Releasing the brakes on antitumor immune response.
Pardoll
D
D
Department of Oncology, Johns Hopkins University Medical School, Baltimore, MD 21205, USA.
D000069594:Abatacept; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology*; D060908:CTLA-4 Antigen; D006801:Humans; D018796:Immunoconjugates; D007167:Immunotherapy; D008213:Lymphocyte Activation; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*; D014612:Vaccines / Q000276:immunology
D000906:Antibodies; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D014612:Vaccines; D000069594:Abatacept